ATE308520T1 - Kombinatorische bibliotheken von indolinone und verwandte produkte und verfahren zur behandlung von krankheiten - Google Patents

Kombinatorische bibliotheken von indolinone und verwandte produkte und verfahren zur behandlung von krankheiten

Info

Publication number
ATE308520T1
ATE308520T1 AT97939480T AT97939480T ATE308520T1 AT E308520 T1 ATE308520 T1 AT E308520T1 AT 97939480 T AT97939480 T AT 97939480T AT 97939480 T AT97939480 T AT 97939480T AT E308520 T1 ATE308520 T1 AT E308520T1
Authority
AT
Austria
Prior art keywords
indolinones
methods
treating diseases
related products
combinatorial libraries
Prior art date
Application number
AT97939480T
Other languages
English (en)
Inventor
Peng Cho Tang
Li Sun
Gerald Mcmahon
Klaus Peter Hirth
Laura Kay Shawver
Original Assignee
Sugen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen Inc filed Critical Sugen Inc
Application granted granted Critical
Publication of ATE308520T1 publication Critical patent/ATE308520T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
    • C07D455/06—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine containing benzo [a] quinolizine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT97939480T 1996-08-23 1997-08-20 Kombinatorische bibliotheken von indolinone und verwandte produkte und verfahren zur behandlung von krankheiten ATE308520T1 (de)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US70223296A 1996-08-23 1996-08-23
US3254696P 1996-12-05 1996-12-05
US3158896P 1996-12-05 1996-12-05
US3158696P 1996-12-05 1996-12-05
US3254796P 1996-12-05 1996-12-05
US3158596P 1996-12-05 1996-12-05
US4556597P 1997-05-05 1997-05-05
US4571597P 1997-05-05 1997-05-05
US4684397P 1997-05-05 1997-05-05
US4556697P 1997-05-05 1997-05-05
US4571497P 1997-05-05 1997-05-05
PCT/US1997/014736 WO1998007695A1 (en) 1996-08-23 1997-08-20 Indolinone combinatorial libraries and related products and methods for the treatment of disease

Publications (1)

Publication Number Publication Date
ATE308520T1 true ATE308520T1 (de) 2005-11-15

Family

ID=27582490

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97939480T ATE308520T1 (de) 1996-08-23 1997-08-20 Kombinatorische bibliotheken von indolinone und verwandte produkte und verfahren zur behandlung von krankheiten

Country Status (8)

Country Link
EP (2) EP1247803A3 (de)
JP (1) JP2001503736A (de)
AT (1) ATE308520T1 (de)
AU (1) AU4155697A (de)
CA (1) CA2264220A1 (de)
DE (1) DE69734521T9 (de)
ES (1) ES2251741T3 (de)
WO (1) WO1998007695A1 (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US6316635B1 (en) 1995-06-07 2001-11-13 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
US6147106A (en) 1997-08-20 2000-11-14 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
US6906093B2 (en) 1995-06-07 2005-06-14 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
US6696448B2 (en) 1996-06-05 2004-02-24 Sugen, Inc. 3-(piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors
AU7622698A (en) * 1996-12-05 1998-06-29 Sugen, Inc. Use of indolinone compounds as modulators of protein kinases
EP0984930B1 (de) * 1997-05-07 2005-04-06 Sugen, Inc. 2-indolinonderivate als modulatoren der proteinkinase-ativität
US6316429B1 (en) 1997-05-07 2001-11-13 Sugen, Inc. Bicyclic protein kinase inhibitors
US6486185B1 (en) 1997-05-07 2002-11-26 Sugen, Inc. 3-heteroarylidene-2-indolinone protein kinase inhibitors
US6987113B2 (en) 1997-06-11 2006-01-17 Sugen, Inc. Tyrosine kinase inhibitors
US6313158B1 (en) 1997-06-20 2001-11-06 Sugen, Inc. Bioavailability of 3-heteroarylidenyl-2-indolinones active as protein tyrosine kinase inhibitors
US6051593A (en) 1997-06-20 2000-04-18 Sugen, Inc. 3-(cycloalkanoheteroarylidenyl)-2- indolinone protein tyrosine kinase inhibitors
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6531502B1 (en) 1998-01-21 2003-03-11 Sugen, Inc. 3-Methylidenyl-2-indolinone modulators of protein kinase
WO1999048868A2 (en) * 1998-03-26 1999-09-30 Sugen, Inc. Heterocyclic classes of compounds for the modulating tyrosine protein kinase
US6514981B1 (en) 1998-04-02 2003-02-04 Sugen, Inc. Methods of modulating tyrosine protein kinase function with indolinone compounds
US6569868B2 (en) 1998-04-16 2003-05-27 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
SK287132B6 (sk) * 1998-05-29 2009-12-07 Sugen, Inc. Farmaceutická kompozícia obsahujúca pyrolom substituovaný 2-indolinón, súprava obsahujúca uvedenú kompozíciu a použitie pyrolom substituovaného 2-indolinónu
KR20010078722A (ko) * 1998-05-29 2001-08-21 아이젠 브란트 게르하르트 고리 의존형 키나제 억제용 약물의 제조를 위한인디고이드 비스인돌 유도체의 용도
DE19824922A1 (de) * 1998-06-04 1999-12-09 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
US6319918B1 (en) 1998-06-04 2001-11-20 Boehringer Ingelheim Pharma Kg Substituted indolinones with kinase inhibitory activity
US6680335B2 (en) 1998-09-28 2004-01-20 Sugen, Inc. Methods of modulating protein tyrosine kinase function with substituted indolinone compounds
WO2000035921A1 (en) * 1998-12-17 2000-06-22 F. Hoffmann-La Roche Ag 4,5-pyrazinoxindoles as protein kinase inhibitors
CA2354510A1 (en) * 1998-12-17 2000-06-22 F. Hoffmann-La Roche Ag 4- and 5-alkynyloxindoles and 4- and 5-alkenyloxindoles
DK1157019T3 (da) * 1998-12-17 2003-07-14 Hoffmann La Roche 4-alkenyl- (og alkynyl-)oxindoler som inhibitorer af cyklinafhængige kinaser, især CDK2
US6153634A (en) * 1998-12-17 2000-11-28 Hoffmann-La Roche Inc. 4,5-azolo-oxindoles
AU760039B2 (en) * 1998-12-17 2003-05-08 F. Hoffmann-La Roche Ag 4-aryloxindoles as inhibitors of JNK protein kinases
CN1356872A (zh) * 1998-12-31 2002-07-03 苏根公司 调节蛋白激酶活性和用于癌症化疗的3－亚杂芳基－2－吲哚满酮化合物
DE60045474D1 (de) * 1999-01-13 2011-02-17 Univ New York State Res Found Neues verfahren zum erschaffen von proteinkinase-inhibitoren
US6624171B1 (en) 1999-03-04 2003-09-23 Smithkline Beecham Corporation Substituted aza-oxindole derivatives
GB9904933D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
US6492398B1 (en) 1999-03-04 2002-12-10 Smithkline Beechman Corporation Thiazoloindolinone compounds
AU3770000A (en) * 1999-03-24 2000-10-09 Sugen, Inc. Indolinone compounds as kinase inhibitors
US6689806B1 (en) 1999-03-24 2004-02-10 Sugen, Inc. Indolinone compounds as kinase inhibitors
AU1928501A (en) * 1999-11-24 2001-06-04 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
US6878733B1 (en) 1999-11-24 2005-04-12 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
US6313310B1 (en) 1999-12-15 2001-11-06 Hoffmann-La Roche Inc. 4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles
WO2001045689A2 (en) 1999-12-22 2001-06-28 Sugen, Inc. Indolinone derivatives for modulation of c-kit tyrosine protein kinase
ES2243461T3 (es) 2000-02-28 2005-12-01 Sugen, Inc. Compuestos de 3-(pirolillactona) -2-indolinona como inhibidores quinasa.
US6620818B1 (en) 2000-03-01 2003-09-16 Smithkline Beecham Corporation Method for reducing the severity of side effects of chemotherapy and/or radiation therapy
MY128449A (en) 2000-05-24 2007-02-28 Sugen Inc Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
EP1294688A2 (de) 2000-06-02 2003-03-26 Sugen, Inc. Indolinon derivate als protein kinase/phosphatase inhibitoren
JP2004502686A (ja) * 2000-06-30 2004-01-29 スージェン・インコーポレーテッド ４−ヘテロアリール−３−ヘテロアリーリデニル−２−インドリノンおよび蛋白質キナーゼ阻害剤としてのその使用
GB0016454D0 (en) 2000-07-04 2000-08-23 Hoffmann La Roche Thienopyrrolidinones
US6504034B2 (en) 2001-01-23 2003-01-07 Hoffmann-La Roche Inc. Naphthostyrils
FR2821358B1 (fr) * 2001-02-27 2006-04-07 Aventis Pharma Sa Oxindoles inhibiteurs de cdk-1 et leur application en therapeutique
DE10114138C2 (de) * 2001-03-16 2003-03-27 Schering Ag Cdk-inhibitorische Indirubinderivate mit erhöhter Löslichkeit
DE10117204A1 (de) * 2001-04-06 2002-10-10 Boehringer Ingelheim Pharma In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
AU2002303892A1 (en) 2001-05-30 2002-12-09 Jingrong Cui 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
DE10134196B4 (de) * 2001-07-13 2005-08-18 Forschungszentrum Karlsruhe Gmbh Technik Und Umwelt Pharmazeutische Zusammensetzung zur Hemmung der unkontrollierten Vermehrung und/oder Induzierung der Apoptose von Zellen
US7005445B2 (en) 2001-10-22 2006-02-28 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors and methods for designing them
GB0302512D0 (en) * 2003-02-03 2003-03-05 Arrow Therapeutics Ltd Compounds
US7157577B2 (en) 2003-03-07 2007-01-02 Sugen Inc. 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors
WO2005068424A1 (en) * 2004-01-20 2005-07-28 Cell Therapeutics Europe S.R.L. Indolinone derivatives as receptor tyrosine kinase ihibitors
NZ561215A (en) 2005-02-22 2010-12-24 Univ Michigan Small molecule inhibitors of MDM2 and uses thereof
WO2006119148A2 (en) * 2005-04-29 2006-11-09 The Ohio State University Research Foundation Keratinocyte growth factor receptor - tyrosine specific inhibitors for the prevention of cancer metastatis
RU2008139599A (ru) 2006-03-07 2010-04-20 Эррэй Биофарма Инк. (Us) Гетеробициклические производные пиразола и способы их применения
US7838542B2 (en) 2006-06-29 2010-11-23 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
HUE030774T2 (hu) * 2007-09-06 2017-05-29 Boston Biomedical Inc Kinázinhibitorokból álló készítmények és felhasználásuk a rák és a kinázokhoz kapcsolódó más betegségek kezelésére
WO2009079767A1 (en) * 2007-12-21 2009-07-02 University Health Network Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer
ES2465971T3 (es) 2009-04-06 2014-06-09 University Health Network Inhibidores de quinasa y método para tratar cáncer con los mismos
EP2556071B1 (de) 2010-04-06 2016-08-17 University Health Network Kinasehemmer und ihre verwendung zur krebsbehandlung
CN103391936B (zh) * 2010-04-30 2016-04-27 国立大学法人东京大学 抗癌剂
CN103183665B (zh) * 2011-12-30 2015-10-14 中国人民解放军军事医学科学院放射与辐射医学研究所 具有酪氨酸激酶抑制活性的物质、其制备方法及用途
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US9642839B2 (en) 2013-06-20 2017-05-09 Institute Of Radiation Medicine, China Academy Of Military Medical Sciences Pla Substance having tyrosine kinase inhibitory activity and preparation method and use thereof
US9642856B2 (en) 2013-10-18 2017-05-09 University Health Network Treatment for pancreatic cancer
MA39776A (fr) 2014-03-24 2017-02-01 Hoffmann La Roche Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf
CN105481751A (zh) * 2014-09-16 2016-04-13 中国科学院海洋研究所 一类2-吲哚酮衍生物及其制备和应用
CN104326964A (zh) * 2014-09-16 2015-02-04 中国科学院海洋研究所 一类氟代2-吲哚酮衍生物及其制备和应用
CN108047119A (zh) * 2017-11-28 2018-05-18 四川理工学院 3-氟烯基氧化吲哚-3-三氟甲基氧化吲哚化合物及其应用
CN107840818A (zh) * 2017-11-28 2018-03-27 四川理工学院 含氟二氧化吲哚化合物及其应用
CN115073353B (zh) * 2021-03-15 2024-05-14 中国医学科学院药物研究所 木脂素类衍生物及其制法和其药物组合物与用途
WO2024149340A1 (zh) * 2023-01-12 2024-07-18 深圳众格生物科技有限公司 具有irak4抑制活性的吲哚酮衍生物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE553661A (de) * 1955-12-23
GB9004483D0 (en) * 1990-02-28 1990-04-25 Erba Carlo Spa New aryl-and heteroarylethenylene derivatives and process for their preparation
GB9115160D0 (en) * 1991-07-12 1991-08-28 Erba Carlo Spa Methylen-oxindole derivatives and process for their preparation
FR2694004B1 (fr) * 1992-07-21 1994-08-26 Adir Nouvelles 3-(Hydroxybenzylidényl)-indoline-2-ones et 3-(hydroxybenzylidényl)-indoline-2-thiones, leurs procédés de préparation, et les compositions pharmaceutiques qui les contiennent.
GB9313638D0 (en) * 1993-07-01 1993-08-18 Erba Carlo Spa Arylidene and heteroarylidene oxindole derivatives and process for their preparation
GB9412719D0 (en) * 1994-06-24 1994-08-17 Erba Carlo Spa Substituted azaindolylidene compounds and process for their preparation
GB9501567D0 (en) * 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
GB9507298D0 (en) * 1995-04-07 1995-05-31 Pharmacia Spa Substituted indolylmethylene-oxindale analogues as tyrosine kinase inhibitors
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease

Also Published As

Publication number Publication date
ES2251741T3 (es) 2006-05-01
CA2264220A1 (en) 1998-02-26
AU4155697A (en) 1998-03-06
DE69734521T9 (de) 2006-12-07
WO1998007695A1 (en) 1998-02-26
EP0929520B1 (de) 2005-11-02
JP2001503736A (ja) 2001-03-21
EP1247803A3 (de) 2002-10-16
DE69734521T2 (de) 2006-07-06
DE69734521D1 (de) 2005-12-08
EP1247803A2 (de) 2002-10-09
EP0929520A1 (de) 1999-07-21

Similar Documents

Publication Publication Date Title
ATE308520T1 (de) Kombinatorische bibliotheken von indolinone und verwandte produkte und verfahren zur behandlung von krankheiten
ATE200156T1 (de) Verfahren,vorrichtung und programm zur synthesebasierten simulation von chemikalien mit biologischen funktionen
DE69732329D1 (de) Verfahren und Vorrichtung zur Trennung einer Schallquelle, Medium mit aufgezeichnetem Programm dafür, Verfahren und Vorrichtung einer Schallquellenzone und Medium mit aufgezeichnetem Programm dafür
ATE230032T1 (de) Verfahren zur herstellung von festen trägern für hybridisierung und zur verminderung von nichtspezifischem hintergrund
DE69608457D1 (de) Verfahren zur identifizierung von mutationen durch ligation vom mehrfach oligonukleotidsonden
DE69724782D1 (de) Verfahren zur herstellung von granulärer mikrobieller biomasse und gewinnung wertvoller komponenten aus mikrobieller biomasse
ATE326473T1 (de) Verfahren zur herstellung von diphosphinen und deren verwendung
DE69939269D1 (de) Verfahren zur bestimmung der suzeptibilität zur sepsisentwicklung und arzneimittel zur behandlung von sepsis
DE69738895D1 (de) Vorrichtung und Verfahren zur Wiedergabe von dreidimensionalem Schall
ATE335498T1 (de) Methode mit hoher durchsatzrate zur funktionellen klassifizierung von in einem genomischen versuchsansatz identifizierten proteinen
DE69922284D1 (de) Vorrichtung und Verfahren zur Wiedergabe von Musik zusammen mit Taktschlaginformation
DE69612457D1 (de) Screening-Verfahren zur Ligand-Identifizierung von Zielproteinen
DE69637605D1 (de) Verfahren zur Identifizierung von Nukleinsäureliganden für Gewebsziele
DE59606881D1 (de) Verfahren und vorrichtung zur herstellung von borstenwaren und danach hergestellte borstenware
DE69911129D1 (de) Vorrichtung und Verfahren zur Musiktonsynthetisierung
DE69604438D1 (de) Integriertes Verfahren zur Methandampfreformierung zur Herstellung von Kohlenmonoxid
DE69632351D1 (de) Verfahren und Vorrichtung zur Musiktonerzeugung
ATE206714T1 (de) Kombinatorisches verfahren zur identifizierung von organometallischen polymerisationskatalysatoren
DE69737360D1 (de) Verfahren zur festphasensynthese von aldehyden, ketonen und hydroxamsäure-derivaten
DE69614769D1 (de) Verfahren und Vorrichtung zur Vernichtung von Reaktionsgas durchVerbrennung
DE69521944D1 (de) Aufnahmeträger für die Begleitung von Video-Liedern und Vorrichtung zur Verwendung dieses Trägers
DE69704528D1 (de) Verfahren und Vorrichtung zur Erzeugung von Musiktönen, zur Bearbeitung und Wiedergabe von Musikdaten mit Hilfe von Speichermitteln
DE59907151D1 (de) Verfahren und Vorrichtung zur intensiven Vermischung von Reaktionsmedien
DE3860637D1 (de) Verfahren und vorrichtung zur herstellung von synthesegas.
ATE219099T1 (de) Verfahren zur identifizierung von verbindungen, die zur behandlung von autoimmunkrankheiten verwendbar sind

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties